difference in volume of distribution of the drug rather than solely from a true difference in hepatic microsomal function. It is stated that some expansion of the extracellular fluid volume remained in the oedematous patients despite three days' treatment with frusemide, and this is confirmed by the lower estimated mean plasma antipyrine concentration at time zero in this group (6.18 $\mu\text{mol/l}$ compared with 6.44, 6.39, and 6.48 $\mu\text{mol/l}$ in groups 1-3 respectively). Thus it is possible that there was a spuriously prolonged half life in the presence of a normal hepatic antipyrine clearance in these patients, and we feel that this possibility deserves fuller consideration.

Finally, we question the validity of administering to oedematous patients a dose of antipyrine calculated from the body weight.

IAN T GILMORE
R P H THOMPSON

St Thomas's Hospital,
London SE1

Management of hypertension

SIR,—Granted that blood pressure is not recorded as often as it might be, both in general practice and in hospital (see Dr R F Heller and Professor G Rose, 4 June, p 1441), we could at least publicise the reading once known. All printed hospital discharge and casualty notes as well as registrar's summaries should include a box for BP. Not only would this enter the GP's record folder, but it might also remind the GP of his obligation to include abnormal readings in his referral letters to hospitals.

RICHARD STONE

London W2

Drug compliance in hypertensive patients

SIR,—Drs A J Marshall and D W Barritt (14 May, p 1278) comment that it is appropriate to test carefully whether patients are more likely to take tablets prescribed only once daily than in daily divided doses and whether calendar packing is feasible and preferable. In their study of atenolol they failed to obtain consistent tablet taking for one-third of the time.

We studied 42 hypertensive patients for 16 weeks—four weeks on conventional oxprenolol three times daily, eight weeks on slow oxprenolol once daily, and a final four weeks back on conventional oxprenolol. Patients were assessed at two-weekly intervals. Conventional oxprenolol was dispensed loose in bottles and slow oxprenolol was dispensed in the manufacturer's calendar packs; a variable number of surplus tablets was supplied each time.

70% of 39 patients took all their tablets, as judged by tablet counting, while on slow oxprenolol. Only three took less than 90%; two took 86% and one 88% of the correct dosage, one of these also complying poorly on conventional oxprenolol. Thus compliance was good on slow oxprenolol in 92% (36 of 39 patients). Two patients withdrew from the study shortly after starting on slow oxprenolol, owing to dizziness and abdominal distension respectively. One patient withdrew for domestic reasons. Thirty-three of 41 patients (80%) preferred slow oxprenolol to conventional oxprenolol.

All patients found that the calendar pack was helpful, particularly in enabling them to determine whether or not they had taken their tablets.

As pointed out in your leading article (26 March, p 793) and by Marshall and Barritt, tablet counting may be misleading and may give an overestimate of compliance. Even allowing for this, however, it is probable that the majority of patients on slow oxprenolol exceeded the 80% value which may be designated as compliance. The full results of this study will be reported elsewhere.

DAVID PERSOFF
ELAINE MASON

St Andrew's Hospital,
London E3

Learnt voluntary control of the heart

SIR,—I was interested in your article on voluntary heart control (11 June, p 1491) because 50 years ago I discovered that I could make my pulse speed up and my pupils dilate while absolutely motionless, much to the amusement of some fellow undergraduates. I had completely forgotten about this but find I have retained the facility.

The technique of learning is rather like that for contracting individual muscles of the leg where one has to transfer a joint-movement volition to a relatively abstract muscular association. Pupil dilatation and heart acceleration were at first achieved by autoinduction of repressed excitement. This is associated with a sort of descending wave of excitement travelling down the body from beneath the sternum, and I suppose one developed a direct ability to provoke that without recourse to any of the original psychological process. I see your references date back to 1971, but I had never heard of anything else of this nature until reading your leading article.

J SHACKLETON BAILEY

Moreton-in-Marsh

Sulphinpyrazone in acute stuttering hemiparesis

SIR,—What does a physician do when confronted by a patient with an acute stuttering hemiparesis? An ischaemic process may be thought likely, but the retrospective diagnosis of transient ischaemia or of completed slow-onset stroke must await the passage of time. The imminent danger of a complete disabling hemiplegia may prompt one to therapeutic intervention, but no treatment is established. Published controlled trials of anticoagulant therapy are not convincing of benefit^{1,2} and anticoagulant treatment of cerebral vascular disease is associated with a high risk of intracranial bleeding,^{3,4} partly because cerebral haemorrhage or tumour cannot be excluded by clinical examination and routine investigations. On the basis that platelet thromboemboli play a role in cerebral ischaemia drugs affecting platelet function, such as sulphinpyrazone, have been studied in patients with transient ischaemic attacks with promising initial results.⁵ We wish to report a patient with an acute stuttering hemiparesis which resolved after initiation of sulphinpyrazone therapy.

A 67-year-old housewife was admitted to hospital six hours after the sudden onset of right-

sided weakness involving the face, arm, and leg. The initial episode lasted 30 min and resolved completely, but weakness recurred one hour later and the patient experienced six episodes of similar duration on the day of admission, four of which were documented by physicians. On admission intermittent dysarthria, lower right facial weakness, and flaccid weakness of the right arm and leg were noted. The optic fundi were normal. An aortic systolic murmur was heard but there were no carotid bruits. Blood pressure on admission was 200/100 mm Hg, falling to 140/80 mm Hg. Investigations did not reveal any relevant pathology. Shortly after admission she was started on sulphinpyrazone 200 mg thrice daily; 18 h later she had only mild subjective right-sided weakness, and by 36 h after admission she was asymptomatic. There was no recurrence of symptoms over the next seven days and she was discharged home on sulphinpyrazone. She was reviewed some six weeks after discharge and was still symptom-free.

Controlled trials of sulphinpyrazone in the management of patients with transient ischaemic attacks and of patients with reasonable recovery from a completed stroke are currently in progress. In addition, controlled trials of antiplatelet agents in patients with unstable cerebral ischaemia, such as we have described, would seem worth while despite the difficulties of definition and the relative rarity of such patients. To prevent completion of an evolving stroke would be desirable, as would early treatment of transient ischaemic attacks. In a recent community study the greatest risk of completed stroke was in the first month after development of transient ischaemic attacks.⁶ Experience with sulphinpyrazone so far suggests that it is a less hazardous treatment than anticoagulants or carotid artery surgery.

GORDON LOWE
RAYMOND V JOHNSTON

University Department of Medicine,
Royal Infirmary,
Glasgow

¹ Carter, A B, *British Medical Journal*, 1961, 2, 70.

² Baker, R N, *et al*, *Neurology*, 1962, 12, 823.

³ Marshall, J, and Shaw, D A, *Lancet*, 1960, 1, 995.

⁴ Hill, A B, Marshall, J, and Shaw, D A, *British Medical Journal*, 1962, 2, 1003.

⁵ Evans, G, in *Proceedings of Eighth Conference on Cerebral Vascular Diseases*, New York, 1973, ed F H McDowell and R W Brennan, p 297.

⁶ Cartledge, N E F, Whisnant, J P, and Elveback, L R, *Mayo Clinic Proceedings*, 1977, 52, 117.

Colony-forming cells and myeloblasts in chronic granulocytic leukaemia

SIR,—The demonstration by Dr A J Barrett and his colleagues (14 May, p 1259) that a relationship exists between colony-forming cells (CFUc) and blast-cell numbers in the peripheral blood of a patient undergoing treatment with splenic irradiation for chronic granulocytic leukaemia (CGL) is of great interest because a relationship between myeloblasts and their presumed progenitor cell can be predicted on kinetic grounds. Their failure to demonstrate a relationship between CFUc and total leucocyte numbers must, however, be a temporary phenomenon reflecting an initially selective effect of splenic irradiation on immature granulocytes since we and others have demonstrated such a relationship in untreated patients, in busulphan-treated patients, and in a patient treated by long-term leucopheresis alone.¹⁻⁴

In most patients with CGL whose leucocyte counts have been reduced or restored to normal during treatment with busulphan blast cells have disappeared from the blood and CFUc numbers are low (but not absent). Such a trend is seen also in Dr Barrett's radiotherapy-treated patient. This

effect vitiates the linearity of the relationship between CFUC and blast cell numbers in treated patients. We have, however, had the opportunity to study a 53-year-old woman with Ph¹-chromosome-positive CGL whose clinical course after diagnosis was atypical. Despite adequate initial treatment with busulphan her spleen remained very large. Blast cells seldom disappeared completely from her blood and she continued to need blood transfusion. For these reasons splenectomy was performed seven months after diagnosis. The spleen weighed 2.75 kg. Thereafter the need for blood was reduced but the percentage of blast cells gradually rose. Some control of leucocyte numbers was achieved first with cyclophosphamide and later with hydroxyurea. In the last six months of her life blast-cell numbers rose steeply and the disease was refractory to busulphan, to hydroxyurea, and to a variety of other drugs used in combination. She died 31 months after diagnosis. Blood CFUC numbers were assayed on eight occasions during the first two years of her disease. Standard agar culture techniques were used.^{1,2} The relation between CFUC numbers and those of total leucocytes and immature leucocytes (blasts plus promyelocytes, predominantly the former) is shown in the figure.

Relation of CFUC to total and immature leucocyte counts.

In this patient there was a clear relation between CFUC and total leucocyte numbers. This observation accords with reports cited above and suggests that such a relationship throughout the chronic phase of CGL is the rule rather than the exception. Our additional finding of a relation between CFUC and immature leucocyte numbers adds support to the contention of Dr Barrett and his colleagues that there is a close relation between the CFUC and the myeloblast. But since these cells are present in the blood in a ratio of about 1:100 (see figure) one can scarcely draw the inference that they must be morphologically similar. Such data as are available on the morphology of the normal human CFUC suggest that they are not.⁶

J M GOLDMAN
D LEWIS
N A BUSKARD

Department of Haematology,
Royal Postgraduate Medical
School,
London W12

- ¹ Goldman, J. M., Th'ng, K. H., and Lowenthal, R. M., *British Journal of Cancer*, 1974, **30**, 1.
- ² Goldman, J. M., et al., *Series Haematologica*, 1975, **8**, 28.
- ³ Moore, M. A. S., *Series Haematologica*, 1975, **8**, 11.
- ⁴ Olofsson, T., and Olsson, I., *Blood*, 1976, **48**, 351.
- ⁵ Pike, B., and Robinson, W. A., *Journal of Cellular and Comparative Physiology*, 1970, **76**, 77.
- ⁶ Dicke, K. A., et al., in *Haemopoietic Stem Cells*, CIBA Foundation Symposium 13, p. 48. Amsterdam, North-Holland, 1973.

Alternatives to medicine

SIR,—Minerva (11 June, p 1539) refers to alternative careers to dentistry and wonders whether there is an organisation that gives details of alternative careers to medicine but in the medical field. There is in fact a booklet called *Alternatives to Medicine*, by Dr John C Thurman, a careers adviser at the University of East Anglia, which gives very useful information indeed about alternative careers to medicine and covers all the important careers in the paramedical field. It is obtainable from Yare Valley Publishers, Robin Hill, 20 Bluebell Road, Norwich NR4 7LF, price 80p including postage.

T L JONES

Senate House,
University of Bristol

Beta-blockers and lipid metabolism

SIR,—In a recent letter (16 April, p 1033), Dr S P Deacon discussed the possibility that long-term treatment with β -adrenergic blocking agents may influence lipid metabolism. Although the acute administration of these drugs seems to lower the levels of free fatty acids,^{1,2} the effect of long-term administration may well be different. In fact Tanaka *et al*³ found that propranolol initially lowered plasma free fatty acids, whereas increased levels were found after 7-8 weeks of treatment. Furthermore, postheparin lipolytic activity, as a reflection of blood triglyceride elimination capacity was lowered. This effect was reversed 10 days after withdrawal of the drug. Such an effect of a β -adrenergic blocking drug is in contrast to what may be expected on a theoretical basis, since adipose tissue lipoprotein lipase activity usually increases under conditions where the mobilisation of lipids from the fat cells is lowered. In addition, Tanaka *et al*³ found a change in the distribution of the plasma lipids in the different lipoproteins. Total lipids in very low density lipoprotein (VLDL) increased but decreased in low-density lipoprotein (LDL) as well as in high-density lipoprotein (HDL). Furthermore, apo-HDL decreased. This finding indeed suggests the need for further studies since a low HDL concentration has been implicated as a risk factor for coronary heart disease.⁴

Fasting blood triglycerides before and after 3 months' treatment with metoprolol

	Before	1 month placebo	3 months' metoprolol
Triglycerides (mmol) . .	1.42 $\pm$ 0.71	1.41 $\pm$ 0.73	1.27 $\pm$ 0.70

Means $\pm$ SD; n = 9.

No significant differences between any group.

We have recently had the opportunity to study nine male patients with moderate hypertension treated with the cardioselective β -blocker metoprolol. The patients were investigated under controlled metabolic ward conditions before treatment, after one month with placebo, and after three months on metoprolol. The dose varied between 50 and 150 mg tid. The plasma triglycerides at these three occasions are shown in table I. In contrast to Waal-Manning⁵ we found no change in the fasting blood triglyceride levels with metoprolol. This discrepancy may be explained by the fact that our studies were performed under controlled conditions while Waal-Manning's

study was performed on an ambulatory basis and possibly included diabetic patients. Also, the possibility that the increase in blood triglycerides noted in Waal-Manning's study may be due to an increased body weight cannot be ruled out, since this information was not reported in her paper. In addition, in our study⁶ no effect of metoprolol on blood triglyceride levels was found when measured postprandially in the upright position before and following physical exercise (bicycle ergometer).

In conclusion, it seems that metoprolol does not increase blood triglyceride levels. Similar findings have been reported with another cardioselective β -blocking agent, practolol, by Ghosh *et al*.⁷ However, in view of the recent results of Tanaka *et al*³ discussed above more careful investigations on the blood-triglyceride-removing capacity as well as the lipids in different lipoprotein moieties are warranted.

A NILSSON
B-G HANSSON
B HÖKFELT

Lund University Clinics,
General Hospital,
S-214 01 Malmö,
Sweden

- ¹ Björntorp, P., et al., *Acta Pharmacologica et Toxicologica*, 1967, **25**, suppl 2, p 51.
- ² Imura, H., et al., *Journal of Clinical Investigation*, 1971, **50**, 1069.
- ³ Tanaka, N., et al., *Metabolism*, 1976, **25**, 1071.
- ⁴ Wiklund, O., et al., *Artery*, 1975, **11**, 399.
- ⁵ Waal-Manning, H. J., *Drugs*, 1976, **11**, suppl 1, p 121.
- ⁶ Nilsson, A., et al., *European Journal of Clinical Pharmacology*, submitted for publication.
- ⁷ Ghosh, P., et al., *Lancet*, 1975, **1**, 9.

Psychotropic drugs and road accidents

SIR,—All practising doctors must share the concern expressed by Dr D C G Skegg and his colleagues on the use of medicines in general practice (18 June, p 1561) over the possible dangers of side effects occurring with psychotropic drugs as a cause of road accidents. Indeed, this possibility is now so well recognised that it is common practice to warn patients about it and to suggest that they do not venture out to the roads during the first few days of therapy until it can be determined whether drowsiness or other side effects may intervene.

There is, of course, another possibility. In untreated cases the patient's judgment may also be impaired by the illness itself. Thus retardation, both mental and physical, and suicidal tendencies in untreated depressed patients must interfere very considerably with their ability to drive a motor vehicle or indeed to avoid one should they be pedestrians. The anxious or phobic patient also is not likely to drive competently, particularly in crowded urban traffic.

It must also be remembered that the majority of patients taking psychotropic drugs do not in fact suffer from side effects that are likely to interfere with driving ability. Thus in a large number of trials conducted by our group in general practice the incidence of drowsiness with chlordiazepoxide amounted to 15% (compared with 6% with placebo) and with amitriptyline to 11%.¹

As with practically every drug tested, there are always conflicting reports concerning efficacy. However, over the 20 years or more that psychotropic drugs have been available to us there have been many hundreds if not thousands of papers recording their effective-